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Relevance: 
In a population of increasing longevity, neurological disorders are becoming more prevalent 
- placing a large strain on NHS resources and funding, as well as an emotional burden 
on those a!ected and their families. One such example is Parkinson’s Disease (PD). This 
neurodegenerative disorder of the basal ganglia is characterised by a progressive loss of 
nigrostriatal dopaminergic transmission, commonly presenting as tremor, bradykinesia, 
rigidity, postural instability, akinesia, and impairments in cognition. Deep brain stimulation 
(DBS) has proven a successful approach to treating PD despite its mechanism of action 
being unclear.
Summary:
 
Three main problems of counteractive outcomes present when identifying a common 
mechanism of DBS within targets. Firstly, contrasting actions of DBS are required to 
explain DBS between targets, such as the GPe and GPi. Secondly, con"icting studies have 
reported both excitatory and inhibitory action of DBS within the same targets. Finally, the 
treatment has also paradoxically proven e!ective in treating hyperkinetic disorders, such as 
Dystonia. There remains no conclusive model for the treatment’s mechanism.
Take Home Messages:
To deliver e!ective treatment and care, it is important for doctors to understand the 
mechanism of action of procedures they are performing. Hence further investigation into 
PD aetiology and DBS action is required. 
ABSTRACT
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In his 1817 Essay on the Shaking Palsy, James Parkinson #rst 
described the symptoms of the eponymous disease - distinguishing 
resting tremor (a pill rolling action) from essential and intention 
tremors. It was not until the turn of the twentieth century that 
attempts were made to target Parkinson’s Disease (PD) via surgical 
intervention; however, many were unsuccessful due to hemiplegia 
o$en being induced. In 1940, Russell Meyers pioneered basal 
ganglia lesioning in PD treatment, reporting improvement of both 
rigidity and tremor. In 1947, Ernest Spiegel and Henry Wycis lead 
a shi$ of treatment towards electrical coagulation procedures on 
the basal ganglia and thalamic nuclei. And in 1952, the implanting 
of electrode contacts into subcortical nuclei began. (1) This would 
ultimately become deep brain stimulation (DBS).
However, this work was soon overshadowed by the discovery of 
dopamine’s modulatory e!ects by Arvid Carlson and colleagues in 
1957. Three years later, a de#cit in striatal dopamine concentrations 
was crucially implicated in PD aetiology by Oleh Hornykiewicz, 
who then went on to pioneer Levodopa (L-DOPA) therapy which 
remains a #rst line treatment for the disease. In 1963, an application 
of DBS to PD was pioneered by Bekthereva and colleagues. (2) 
Via use of pacemakers, it became the #rst controlled and reversible 
PD therapy and met FDA approval in 1997 for the treatment of 
PD and idiopathic tremor. DBS also proved useful experimentally 
as it allows for double blind trials. As summarised in Figure 1, 
three basal ganglia pathways have been implicated in the control 
of movement. Multiple structures involved in these pathways are 
approved targets for DBS, including: the subthalamic nucleus 
(STN), globus pallidus Internus (GPi), and the ventral intermediate 
nucleus of the thalamus (VIM). The globus pallidus externus 
(GPe), subthalamic nucleus/Substantia nigra pars reticulata (STN/
SNr) combined, and GPe/GPi combined DBS have also proven 
successful in treating the disease within laboratory conditions.
Despite its mechanism remaining unclear, DBS replaced lesioning 
therapies as the most common surgical option for PD patients who, 
though still responsive to pharmacological management, su!er from 
periods of severe motor complications or dyskinesia. To this day, 
PD medications can only alleviate symptoms; none stop or delay 
the degeneration of nigrostriatal neurons. Furthermore, there is at 
current a 50% chance of patients with early onset PD developing 
drug-induced dyskinesias within 5 years of pharmacological 
management. (3) DBS o!ers a reversible alternative with fewer 
reported side e!ects. 
Figure 1: Diagram of basal-ganglia connections. Pink nuclei 
denote approved DBS targets for PD and blue shaded structures 
are those which have been successful in experimental studies. Note 
Direct (cortico-striato-nigral), indirect (cortico-striato-pallido-
subthalamo-nigral), and hyperdirect (cortico-subthalamo-nigral) 
pathways.
 
Models of Parkinson’s Disease
At present there are three leading models for the progression of 
Parkinson’s disease.
The #rst is changes in SNr/GPi Firing Rates. Here depleted 
concentrations of dopamine result in both a reduction of tonic 
inhibition of the indirect pathway and excitation of the direct 
pathway.  Cumulatively, this results in reduced striatal inhibition 
of the SNr/GPi output nuclei. This model explains bradykinesias 
and akinesia. Conversely, increased SNr/GPi activity may explain 
hyperkinetic disorders such as Dystonia. However, tremors are 
poorly accounted for.
PD tremors have instead been suggested to be result of oscillatory 
GPe-STN-GPe activity. (4) Here reduced dopaminergic 
modulation of the indirect pathway results in a continuous cycle of 
GPe inhibition, STN disinhibition, reciprocal glutamatergic GPe 
excitation, STN inhibition, and the cycle continues. This model 
is supported by DBS electrode recordings of PD patients showing 
oscillatory local #eld potentials in the basal ganglia. (5)
A third, rather elegant model suggests that temporal di!erences 
of activity in direct, indirect, and hyperdirect pathways induce 
GPi/SNr ‘dynamic activity’ to alter thalamic input in a centre-
surround formation. This is supported by triphasic GPi responses 
of early excitation, inhibition, and subsequent excitation. (6) Initial 
thalamic motor commands are reset by hyperdirect pathway action, 
then the direct pathway disinhibits centre thalamic #eld to execute 
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a motor command. Lateral inhibition maintains suppression of 
surrounding commands. Finally, delayed indirect pathway activity 
di!usely inhibits all commands. In PD, a de#cit of dopaminergic 
transmission increases the ratio of indirect: direct pathway #ring. 
The consequent temporal shortening and spatial narrowing of 
GPi inhibition, helps explain the PD symptoms of bradykinesia, 
akinesia, and rigidity. This broad thalamic disinhibition increases 
probability of competitive motor commands being generated, 
resulting in involuntary movements: tremors.
DBS Con!guration
The modern-day DBS system consists of three components:   
- A lead containing electrode contacts at the tips (o$en Tungsten) 
which create a cylindrical contact with the surrounding tissue to 
stimulate the target.
- An extension wire passing under the skin of the head, neck, and 
shoulder.
- A pacemaker, o$en subclavicular, generating a controllable pulse 
of stimulation to the lead. 
DBS leads are commonly one of two variants: monopolar or 
bipolar. The former involves implanting a cathode contact within 
the targeted structure. The pacemaker acts as the anode, creating a 
spherical stimulation #eld at the cathode. As current "ow is greatest 
at proximity to the cathode, anodal implantation is not performed 
during monopolar DBS. Bipolar DBS involves both contacts within 
a single lead being inserted and connected to a pacemaker in the 
chest cavity. These contacts, less than 1mm apart, create elliptical 
stimulation #elds allowing for a more precise targeting of tissue. 
Alternative ‘multipolar’ methods of DBS are under research to 
assess whether they may o!er greater therapeutic bene#t. One such 
example is tripolar DBS with two cathodes and one anode. (7) 
Figure 2 Le$: Diagram of DBS components: the electrode (here 
targeting the STN) is shown in red and is connected via a lead 
(blue) to a subclavian pacemaker (grey).
Monopolar DBS is the most popular as it requires a lower level of 
stimulation to attain identical therapeutic bene#t to bipolar DBS 
as the space between contacts is greater, therefore a larger volume 
of tissue is activated. Hence, battery longevity is greater and fewer 
operations to replace batteries are required.
The pacemaker system itself can also be one of two types: 
voltage-controlled stimulation (VCS) and current-controlled 
stimulation (CCS). (8) Adapted from cardiac pacemakers, VCS is 
the traditional approach. However, as the immune system targets 
the foreign electrode, tissue builds up at the contacts. This results 
in impedance changes and consequently current "uctuations and 
charge accumulation, ultimately leading to over-stimulatory side-
e!ects. To counter this, and maintain a constant output, a parallel 
arrangement of capacitors absorbs surplus charge and discharges 
when needed. This increases pacemaker size and mass, making 
implantation more invasive. The uniform "ow of electrons in 
CCS overcomes these issues. However, this requires a large output 
headroom and a lower voltage swing compared to the near 100% 
attained by VCS. The amount of charge supplied, and its rate of 
delivery can be controlled by adjusting the pulse width, current/
voltage supply, and the frequency of stimulation. As current 
"uctuations are absent in CCS, it is easier to control pulse width 
than in VCS.
‘Excitation vs. Inhibition’ Debate
As there is no unanimously accepted PD model, it is unsurprising 
that contradictory e!ects of DBS action have been reported in 
PD treatment. This paper will now explore DBS action within 
individual targets.
i. GPi-DBS
GPi stimulation was shown in 1996 to alleviate rigidity and 
bradykinesia in MPTP treated monkeys. (9) As pallidotomies were 
a successful approach in the 1990s, GPi-DBS was long accepted to 
act via inhibiting neurons. However, a reduction of activity in 77% 
of sampled, responsive thalamic neurons (mostly VA and VLo) in an 
awake macaque monkey indicates that the GPi is instead excited by 
DBS. (10) Only 16% of the thalamic neuron pool were shown to 
have a higher rate of #ring during GPi stimulation. The decrease in 
thalamic activity was suggested to obstruct abnormal #ring patterns 
causative of PD. Additionally, increased thalamic activation has 
been explained by antidromic current propagation during GPi-DBS 
treatment of Dystonia patients. (11) The excitation model is further 
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supported by recordings of decreased primary motor cortex activity 
during GPi-DBS. (12)
GPi stimulation is o$en performed at 130-185Hz, 60–90µs pulse 
width, and at a constant voltage of 1-3.6V – parameters optimal for 
exciting GPi axons rather neural soma. (6) Hence GPi-DBS action 
may be due to downstream excitation via GPi e!erent neuronal 
current spread, despite a reduction or no change in the activity of 
the GPi itself. However, this is further complicated by GPi-DBS 
studies on PD monkeys reporting multiphasic responses of both 
excitation and inhibition. This may be due to activation of both 
GABAergic and glutamatergic terminals. (13) 
ii. STN-DBS
As lesioning of the STN signi#cantly reverses PD symptoms in 
MPTP treated monkeys (14), initial studies hypothesised STN-
DBS to act via inhibiting STN activity. (15) This was thought 
to be via a depolarisation blockade; however, voltage gated 
channel inactivation has also been recently proposed. (16) Later 
studies reported that 44% of STN neurons inhibited by high 
frequency stimulation exhibited both early inhibitory and rebound 
excitatory phases; thus indicating a role of hyperpolarisation. (17) 
Furthermore, VL neuronal activity increases during STN-DBS, 
indicating inhibited STN-GPi input (18) 
Con"icting studies report increased GPi and GPe activity of MPTP 
treated monkeys during STN-DBS. (19) Additionally, a trial on 
10 PD patients showed SNr activity to be increased during and 10 
minutes a$er 130Hz STN stimulation. (20) Hence it is likely that 
if STN neurons are excited during local DBS, they consequently 
stimulate GPe, GPi, and SNr neurons via e!erent glutamatergic 
projections.
An explanation for this con"iction is that STN-DBS inhibits the 
soma of STN neurons while simultaneously exciting their axons, 
resulting in downstream stimulation of interconnected basal ganglia 
nuclei. (21) This explains unchanged activity in GP neurons 
despite reduced STN activity and #ring rates in other nuclei being 
similar to stimulation pulse rate. Additionally, this mechanism 
has been proposed to incorporate antidromic activation of GPi-
STN e!erents, though their presence is inconsistent with other 
anatomical studies. (22).
A study has also suggested STN-DBS to both inhibit and excite 
di!erent populations of STN neurons. (23) These e!ects were 
attributed to stimulation of glutamatergic and GABAergic a!erent 
axon terminals. Stimulation also increased SNc activity, possibly 
explained via STN-SNc e!erent activation.
iii. GPe-DBS
GPe stimulation alleviates bradykinesia and akinesia in Parkinsonian 
monkeys. (24) This induces a repeating cycle of GPi suppression, 
brief activation, and 5ms latent prolonged suppression, restoring 
SNr/GPi #ring rates to those seen in non-Parkinsonian monkeys. 
Additionally, oscillatory GPe and STN activity is reduced, hence 
supporting all three PD models.
GPe-DBS has also been shown to excite and inhibit di!erent 
GPe neuronal groups. (6) GPe neurons receiving single-pulse 
stimulation exhibited either a biphasic neuronal response of initial 
inhibition and subsequent excitation or prolonged inhibition with 
no excitation. Repetitive stimulation produced both excitatory and 
inhibitory e!ects.
Biphasic activity of neurons may be due to post-hyperpolarisation 
rebound spiking. Di!ering e!ects between neuronal groups can 
be explained in line with the excitation model of DBS: variances 
in densities of neurons projecting into the GPe induce di!ering 
responses to GPe stimulation. (25) This is supported by injections 
of GABAA antagonist Gabazine eradicating inhibitory response to 
stimulation and combined administration of AMPA and NMDA 
channel blockers NBQX/CPP abolishing excitatory e!ects. The 
Oscillatory Firing Pattern model of PD also explains the biphasic 
recordings: an inhibition of the GPe during DBS would decrease 
activity of GPe-STN GABAergic neurons, in turn disinhibiting the 
STN and increasing activity of STN-GPe glutamatergic neurons. 
This would result in phases of inactivation and activation of the GPe 
in an oscillatory manner.
iv. Combined DBS
A trial has recently investigated the therapeutic bene#t of GPe-
DBS, GPe/GPi combined-DBS, and pharmacological PD 
management in patients who had previously undergone GPi-DBS. 
(26) GPe-DBS was more e!ective than GPi-DBS. However, 
combined DBS was by far the most e!ective treatment, suggesting 
a synergistic mechanism. GPi-DBS was more e!ective treatment in 
the long run. As observed earlier, excitation of GPe and inhibition 
of GPi best explain the e!ects of DBS in line with the #ring rate 
and oscillatory #ring pattern models. GPe/GPi combined-DBS 
evidently presents a paradox. I suggest that these contradictory 
e!ects may be explained by activation of glutamatergic a!erents 
in the GPe and GABAergic terminals in the GPi. However, 
this speci#city of DBS targeting is contradicted by many of the 
aforementioned observations of mono GPe- and mono GPi- DBS. 
Combined GPe/GPi-DBS doesn’t fall in line well with the dynamic 
activity PD model.
Additionally, a double-blind study suggested STN/SNr 
combined-DBS as a novel treatment in alleviating PD refractory 
gait disturbances. (27) This is supported by SNr (mono)-DBS 
alleviating forelimb akinesia in hemi-Parkinsonian rats. (28)
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v. VIM-DBS
The ventral intermediate nucleus (VIM) of the Thalamus receives 
input mainly from the cerebellum and projects to the primary 
motor cortex to aid in the coordination of movement. Bypassing 
the basal ganglia entirely, unilateral VIM-DBS was as bene#cial 
as, and produced similar side-e!ects to, unilateral thalamotomy. 
However, stimulation is reversible and also safer to use on elderly 
patients. It was hypothesised that the mechanism of this is via 
inhibiting neurons of a transcortical re"ex loop. (29) A 6-year 
multicentre follow up study showed monopolar VIM-DBS to 
signi#cantly reduce contralateral tremor with p-values of < 0.00001. 
(30) Additionally, a > 60% decrease in average contralateral tremor 
scores in the ‘o!-state’ was observed compared to baseline #gures, 
suggesting that VIM-DBS induces permanent physiological 
changes in alleviating tremor. The nucleus remains a DBS target in 
alleviating upper extremity tremor and is easier to surgically access 
than the STN.
Disruption Hypothesis
Following their work identifying GPi-DBS to inhibit both arti#cial 
cortical response and spontaneous discharge via activation of 
GABAergic a!erents, Chiken and Nambu hypothesised a third 
DBS mechanism: GPi-DBS activates a!erent axon terminals and 
dissociates them from e!erent projections, hence ‘blocking’ the "ow 
of information through the output nucleus. (6) The mechanism for 
this is in essence synaptic fatigue; stimulated neurons excessively 
release neurotransmitter and so cannot respond to further action 
potentials as their transmitter stores have been depleted.
A disruption model of DBS action would fall in line with all three 
PD models as any abnormal PD basal ganglia activity - be it #rings 
patterns, rates, or dynamic activity changes - passes through the 
GPi. The mechanism may also explain the counterintuitive e%cacy 
DBS has in treating dystonia: involuntary movement commands, 
as explained by the dynamic activity model, are blocked by GPi 
stimulation. Based on reports of direct pathway inhibition of 
the SNr not being a!ected by STN stimulation (31), it was also 
suggested that STN-DBS ‘blocks’ hyperdirect and indirect pathway 
excitation of the SNr. This would explain the treatment’s ability to 
alleviate bradykinesia and rigidity in PD patients.
Discussion
Depolarisation blockade, voltage-gated channel inactivation, and 
GABAergic a!erent activation have been suggested to explain 
inhibitory e!ects of DBS action. Axonal stimulation, particularly of 
glutamatergic a!erents, has also been proposed to account for DBS’s 
excitatory e!ects.
Evidently there is a contradiction in action of DBS. Based on the 
disruption hypothesis, this review suggests that these observations 
are in fact not antagonistic but rather synergistic in nature. 
Observed e!ects vary due to glutamatergic and GABAergic neuron 
pools being investigated, but in either case excessive transmitter 
release reduces abnormal information "ow in the stimulated 
nucleus.
I also suggest that this hypothesis may explain the sustained 
e!ects of DBS when stimulation is turned o!. That is, prolonged 
stimulation of a!erent axon terminals may instigate a long-term 
depression mechanism due to excessive bouton polarisation. A 
reduction of neurotransmitter release sites on the presynaptic 
membrane would decrease response to action potentials, essentially 
‘blocking’ information "owing through. Support for this comes 
from hippocampal GABAergic synapses exhibiting a long-term 
reduction of GABA release probability as result of presynaptic 
NMDA-mediated calcium in"ux. (32)
GPe-DBS is likely explained by an increase in GPe activity or the 
activation of GABAergic e!erents projecting to the STN. However, 
GPe-DBS may also be explained by a disruption mechanism. As the 
GPe has been shown to have high intrinsic activity (33), stimulation 
disrupting GPe input would result in greater inhibition of the STN 
and output nuclei. This falls in line with Vitek and colleagues’ 
study explored earlier. (24) Additionally, tremor symptoms may be 
alleviated due to reduced GPe-STN oscillatory #ring.
However, the disruption hypothesis raises some issues. Firstly, in 
the STN and GPi the suggested e!ects are near indistinguishable 
with those supporting the inhibition hypothesis. Secondly, 
reduced direct pathway activity, as a result of nigrostriatal 
neurodegeneration, is not compensated for by GPi-DBS in this 
hypothesis. If anything, the remaining direct pathway input to 
the GPi is too being blocked by this mechanism, along with 
hyperdirect and indirect pathways, resulting in intrinsic GPi #ring. 
As PD symptoms are drastically reduced to near-normal values of 
symptom scores, this hypothesis undermines previously held views 
of the role of the basal ganglia in motor control. Thirdly, a study 
on rodent optogenetics showed selective activation of hyperdirect 
(cortico-STN) neurons to alleviate PD symptoms. (34) This 
contradicts an STN-DBS mechanism of disrupting hyperdirect 
pathway information "ow. Furthermore, observations of post-
inhibitory rebounds a$er stimulation cannot be accounted for by 
disruption as the tissue is polarised. Instead a delay and subsequent 
neurotransmitter release would be expected.
Conclusion 
The STN and GPi are approved targets e!ective in alleviating 
debilitating PD symptoms. For those su!ering from tremor 
dominant PD, additional bene#t may be found from VIM-DBS. 
Though parameters vary by the structure targeted, e!ective 
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DBS ranges are 130-200Hz frequency, 60-100µs pulse width, and 
1-5.5V constant voltage. Monopolar DBS requires a lower level of 
stimulation and hence o!ers more optimal battery life. However, 
bipolar and multipolar approaches are favourable for those with side 
e!ects from stimulation. GPe, SNr, and combined DBS may o!er 
alternative future strategies.
DBS has been shown to induce both inhibitory and excitatory e!ects. 
A disruption view of DBS action may explain a synergy between 
these observations. However, this may also be explained by Moran 
et al.’s hypothesis of simultaneous somatic inhibition and axonal 
stimulation. Although, a disruption mechanism would account for 
the bene#t of DBS in treating hyperkinetic disorders. 
Generally, the #ring rate PD model seems to best explain the 
inhibitory e!ects of DBS. While both inhibitory and excitatory 
hypotheses of DBS action fall in line with oscillatory #ring patterns. 
The disruption hypothesis supports both of these models as well as 
Nambu et al.’s work on ‘dynamic activity’. 
As there is no unanimously agreed representation of basal ganglia 
connections, there remains no absolute model for PD aetiology, 
and consequently a lack of consensus on DBS action. There is no 
question that DBS has proven an e!ective approach to PD therapy 
and has paved the way for examining basal ganglia action. However, 
further investigation into the relationship between cortico-baso-
thalamic connections and PD is required to gain a better view on the 
mechanism of DBS and re#ne its application in PD treatment.
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